Dr. Winter on Checkpoint Inhibitors for Hodgkin Lymphoma

Jane N. Winter, MD
Published: Tuesday, Oct 24, 2017



Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Checkpoint inhibition might have some toxicity issues, explains Winter. However, the CheckMate-205 trial, presented by Michelle A. Fanale, MD, at the 14th International Conference on Malignant Lymphoma in Lugano, Switzerland, indicated that there has been little to no serious toxicity in the patients who received nivolumab (Opdivo).

Winter is hopeful that these agents for patients with Hodgkin lymphoma will have a low toxicity profile.


Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Checkpoint inhibition might have some toxicity issues, explains Winter. However, the CheckMate-205 trial, presented by Michelle A. Fanale, MD, at the 14th International Conference on Malignant Lymphoma in Lugano, Switzerland, indicated that there has been little to no serious toxicity in the patients who received nivolumab (Opdivo).

Winter is hopeful that these agents for patients with Hodgkin lymphoma will have a low toxicity profile.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x